Aleniglipron or Placebo + Aleniglipron or Placebo + Aleniglipron or Placebo + Aleniglipron + Aleniglipron + Aleniglipron + Aleniglipron
Phase 2Active 1 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obesity, Overweight, or Chronic Weight Management
Conditions
Obesity, Overweight, or Chronic Weight Management
Trial Timeline
Oct 17, 2024 → Aug 1, 2026
NCT ID
NCT06693843About Aleniglipron or Placebo + Aleniglipron or Placebo + Aleniglipron or Placebo + Aleniglipron + Aleniglipron + Aleniglipron + Aleniglipron
Aleniglipron or Placebo + Aleniglipron or Placebo + Aleniglipron or Placebo + Aleniglipron + Aleniglipron + Aleniglipron + Aleniglipron is a phase 2 stage product being developed by Structure Therapeutics for Obesity, Overweight, or Chronic Weight Management. The current trial status is active. This product is registered under clinical trial identifier NCT06693843. Target conditions include Obesity, Overweight, or Chronic Weight Management.
What happened to similar drugs?
20 of 20 similar drugs in Obesity, Overweight, or Chronic Weight Management were approved
Approved (20) Terminated (5) Active (0)
Hype Score Breakdown
Clinical
12
Activity
12
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06693843 | Phase 2 | Active |
Competing Products
20 competing products in Obesity, Overweight, or Chronic Weight Management
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MK0493 | Merck | Phase 2 | 35 |
| MK0557 | Merck | Phase 3 | 40 |
| AMG 786 | Amgen | Phase 1 | 29 |
| Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide Placebo | Eli Lilly | Phase 2 | 39 |
| Tirzepatide | Eli Lilly | Phase 2 | 42 |
| exenatide + Placebo | Eli Lilly | Approved | 43 |
| Brenipatide | Eli Lilly | Phase 1 | 36 |
| Orforglipron + Placebo | Eli Lilly | Phase 3 | 47 |
| TERN-601 | Terns Pharmaceuticals | Phase 2 | 32 |
| MBX 4291 + Placebo | MBX Biosciences | Phase 1 | 30 |
| PG-102 | Rani Therapeutics | Phase 1 | 26 |
| Orforglipron + Placebo | Eli Lilly | Phase 1 | 29 |
| Tirzepatide + Placebo | Eli Lilly | Phase 3 | 40 |
| Eloralintide + Placebo | Eli Lilly | Phase 1 | 29 |
| Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide Placebo | Eli Lilly | Phase 2 | 27 |
| LY3437943 + Midazolam + Warfarin + Caffeine | Eli Lilly | Phase 1 | 29 |
| Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injection | Skye Bioscience | Phase 2 | 29 |
| Tirzepatide | Eli Lilly | Approved | 50 |
| Adenosine + Regadenoson | Astellas Pharma | Pre-clinical | 26 |
| Micafungin + Micafungin | Astellas Pharma | Approved | 43 |